Hangzhou Meiya Pharmaceutical Co., Ltd.-Industry Trends

News Dynamics

Provides you with the latest company and industry information

Stay up to date with the latest company news and upcoming events

Repurposing Toxins as Signals: How the Kongming System Achieves Ultrasensitive Immunity Through Filament-Mediated Allostery

넶0 2026-02-04
Decoding the Tumor's Invisible Shield: CARM1-ALIX Axis Drives Hypoxanthine-Enriched Exosomes to Subvert CD8+ T Cell Immunity

넶0 2026-01-28
AHCY-Adenosine Complex: A Novel Prognostic Biomarker and Precision Therapeutic Target in Cancer

넶2 2026-01-22
From Bench to Bedside: Targeted mRNA Delivery Achieved with Sustainable, Lyophilizable Nanoparticles

넶1 2026-01-16
Professional Perspective: "mRNA Technology Breaks the 40-Year Deadlock in HIV Vaccine Development"

넶0 2026-01-13
More Potent, Less Toxic: How a Novel MeDZ Lipid is Revolutionizing mRNA Cancer Vaccines

넶1 2026-01-05
A New Dawn for Hepatitis B Treatment: Can mRNA and Gene Editing Deliver a Cure?

넶3 2025-12-31
Breaking the Cycle of Non-Healing Diabetic Ulcers: Multifunctional Aerogel Dressing Offers a Comprehensive Therapeutic Strategy

넶6 2025-12-25

About Meiya

Product Center

Service Support

Related Links

Address

Headquarters: Hangzhou Meiya Pharmaceutic

al Co., Ltd.

Room 101, Building 12, Yinhai Science and Tech

nology Innovation Center, 501 Fucheng Road,

Xiasha Street, Qiantang District, Hangzhou City,

Zhejiang Province

Sales Company: Shanghai Nucleotide Biotec

hnology Co., Ltd.

Production base: Meiya Pharmaceutical Hai

an Co., Ltd.

Copyright©2025 Hangzhou Meiya Pharmaceutical Co., Ltd.